| (USD) | Sep 2023 | Q/Q |
|---|---|---|
| Revenue | 12.4MM | +80% |
| Gross Profit | - | - |
| Cost Of Revenue | - | - |
| Operating Income | -84.7MM | -1% |
| Operating Expenses | - | - |
| Net Income | -71.7MM | -2% |
| R&D | 45.5MM | +8% |
| G&A | 40.7MM | +1% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
This small biotech is struggling to fly -- and investors should probably steer clear.
Who wins this face-to-face between two beaten-down biotechs?
This company has proven its innovative abilities, but that's not enough to outperform the market.
SOMERVILLE, Mass., April 11, 2024--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Compensation Committee of the Company’s Board of Directors approved inducement grants of 102,700 restricted stock units ("RSUs") to twelve newly hired employees with a grant date of April 9, 2024 (the "Inducement Grants"). The Inducement Grants are subject to the terms and conditions of award agreements covering the grants and the Company’s 2021 Inducement Plan.
bluebird bio, Inc. (NASDAQ:BLUE) Q4 2023 Earnings Call Transcript March 26, 2024 bluebird bio, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and welcome to bluebird bio Fourth Quarter and 2023 Annual Results Conference Call. At this […]
Biotech stocks are famously volatile. One analyst feels this one could be volatile enough to produce an outsized gain.
SOMERVILLE, Mass., March 26, 2024--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported fourth quarter and annual financial results and business highlights for the year ended December 31, 2023, including recent commercial and operational progress.
SOMERVILLE, Mass., March 25, 2024--bluebird bio, Inc. (Nasdaq: BLUE) announced today that it will host a conference call to discuss fourth quarter and 2023 annual results and business updates on March 26, 2024, at 8:00 a.m. ET.
The company was thrown a financial lifeline.
SOMERVILLE, Mass., March 18, 2024--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today announced that it has entered into a $175 million five-year, term loan facility with Hercules Capital, Inc. (NYSE: HTGC) ("Hercules"). The transaction strengthens the Company’s balance sheet as it executes on the commercial launches for its three FDA approved gene therapies – LYFGENIA for sickle cell disease, ZYNTEGLO for beta-thalassemia and SKYSONA for cerebral adrenoleukodystrophy.